# Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (RFA-NS-26-001)

**Plain-English Eligibility Score:** 68/100

| Field | Value |
|---|---|
| Opportunity number | RFA-NS-26-001 |
| Title | Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) |
| Agency | National Institutes of Health |
| Status | posted |
| Posted / open date | 2026-05-04 |
| Close date | 2026-11-10 |
| Award ceiling | n/a |
| Award floor | n/a |
| Estimated total funding | $40,000,000 |
| Funding category | Health |
| Eligible applicants | City or township governments; For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Public housing authorities/Indian housing authorities; Native American tribal governments (Federally recognized); County governments; State governments; Special district governments; Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments); Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Public and State controlled institutions of higher education |
| Eligibility notes | Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to support a marketing application) supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is  |
| CFDA / Assistance listing | 93.853 |
| Summary | The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS. |
| Agency contact | NINDSALSMailbox@mail.nih.gov |

## Why this score
- Small businesses are listed as eligible applicants.
- Nonprofits are listed as eligible applicants.
- Only 6 days until the deadline.

Source: Grants.gov (U.S. Department of Health and Human Services) (https://www.grants.gov/search-results-detail/360400). Last refreshed: 2026-11-03T18:08:06.385Z.
Data from Grants.gov. Always read the full notice of funding opportunity before applying. Informational only; not legal or grant-writing advice.